The two firms will jointly investigate the technical and clinical feasibility of using Oncos oncolytic adenoviruses to deliver Abiprot antibodies to mutant RAS genes, which tend to be hard to reach.

"If successful, this would provide a first-in-class oncolytic virus candidate directly targeting RAS and demonstrate proof-of-concept for Oncos-Abiprot as a new technology platform," the companies said in a statement released June 29.

Innovations in synthetic chemistry help identify new cancer therapies
The pathway to discovering and developing cancer therapies is not always linear, but well-designed models incorporating smart chemical innovations can...

Lyell and Pact partner on T-cell therapy
Lyell Immunopharma and Pact Pharma have formed a strategic partnership to jointly develop and test a next-generation personalized anticancer T-cell therapy...

Oblique Therapeutics identifies epitope for SARS-CoV-2 antibodies
Oblique Therapeutics has used its Abiprot antibody discovery platform to identify an epitope in SARS-CoV-2 that may facilitate the generation of new neutralizing...

CNS Pharma partners with MD Anderson
Cancer biopharmaceutical company CNS Pharmaceuticals has entered into a sponsored research agreement with the University of Texas MD Anderson Cancer Center...